clinical trial · NCT07664553
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Type 2 Diabetes MellitusElecoglipronPlacebo
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
started
Jul 8, 2026
primary completion
May 23, 2028
completion
May 23, 2028
last updated
Aug 4, 2026
official title
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol